SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
Abstract Background Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). Methods W...
محفوظ في:
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2021-02-01
|
| سلاسل: | Cardiovascular Diabetology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12933-021-01243-4 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|